

PHARMACY FORMULARY UPDATES EFFECTIVE 12/1/2016

MVP Health Care's Pharmacy & Therapeutics (P&T) Committee has determined that the following drugs, which have been recently approved by the FDA, will require **prior authorization** for at least the first six months following the date they are available on the market. The most current versions of our Formularies and Prior Authorization forms are available at www.mvphealthcare.com

New Drugs (prior authorization required)

Drug Name	Indication	Commercial & Marketplace Tier	Medicare Part D Tier	MVP Medicaid
Afstyla	Hemophilia A	Medical	Part B	Not covered
Epclusa	Hepatitis C	Tier 2/Tier 3 Market	Non-formulary	Tier 2
Zinbryta	MS	Tier 3	Non-formulary	Non-formulary
Vonvendi	Von Willebrand disease	Medical	Part B	Not covered
Xiidra	Dry eyes	Tier 3	Non-formulary	Non-formulary
Bevespi Aerosphere	COPD	Tier 3	Non-formulary	Non-formulary
Byvalson	Hypertension	Tier 3	Tier 4	Non-formulary
Qbrelis	MI	Tier 3	Non-formulary	Non-formulary
Zurampic	Gout	Tier 3	Non-formulary	Non-formulary
Sustol	N/V due to chemotherapy	Medical	Medical	Medical
Otovel	Otitis media	Tier 3	Non-formulary	Non-formulary
Exondys 51	DMD	Medical	Medical	Medical
Cuvitru	Immunodeficiency	Medical	Non-formulary	Medical
Taytulla	Acne vulgaris	Tier 3	Non-formulary	Non-formulary
Kyleena	Contraception	Medical	Non-formulary	Non-formulary

For Commercial & Exchange (non-Medicare) business:

Formulary additions/changes			
Drug Name	Tier	Drug Name	Tier
Nilutamide	1(Tier 2 Exchange)	Aripiprazole ODT	1(Tier 2 Exchange)
Ethacrynic acid	1(Tier 2 Exchange)	Yuvaferm	1(Tier 2 Exchange)
Olmesartan/HCT	1(Tier 2 Exchange)	Olmesartan-amlodipine	1(Tier 2 Exchange)

Drugs removed from PA for Commercial & Exchange business:

Iressa	Darzalex ^M	Portrazza ^M	Alecensa	Bendeka ^M
Propel Implant	Seebri Neohaler	Utibron Neohaler	Vistogard ^M	Odefsey
Otiprio	Descovy			

*May be covered under Part B if administered in the office or outpatient setting.
M- medical benefit + Step Therapy QL-Quantity Limits apply

If you have any questions with respect to this notice, please contact your Professional Relations Representative.

